Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients
undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would …

Background The aim of the study was to compare the efficacy and safety of bivalirudin
versus unfractionated heparin (UFH) in patients with acute myocardial infarction who …

The results of randomized trials and observational studies make a strong argument for the
use of bivalirudin rather than heparin plus systematic glycoprotein (GP) IIb/IIIa inhibitors for …

Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …

Introduction: Bivalirudin and heparin are the two most commonly used anticoagulants used
during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled …

Background The aim of this study was to assess the impact of bivalirudin, as compared to
unfractionated heparin, on clinical outcomes in patients with ST‐segment elevation …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

BACKGROUND: Bivalirudin is replacing heparin as the anticoagulant agent of choice for
elective percutaneous coronary intervention (PCI). This study aimed to assess the safety and …

Objective: This study evaluates outcomes with bivalirudin vs heparin in various patient
subgroups and the overall population during percutaneous coronary interventions (PCI) …

Introduction: Anticoagulant therapy is critical to prevent ischemic recurrences and
complications in acute coronary syndrome (ACS) patients undergoing percutaneous …